PB CD4⁺TCRζ^dim T cells retain the capacity to migrate in vitro despite anti-TNF treatment in vivo. PBLs acquired from patients with RA at baseline and 14 weeks after treatment with anti-TNF were analyzed for their capacity to migrate in vitro using the transendothelial migration assay. Migrating cell subsets were determined by flow cytometry. Data are expressed as percent cells migrating for (A) PBLs and CD3⁺TCRζ^dim T cells, (B) CD4⁺TCRζ^dim and CD8⁺TCRζ^dim T cells, and (C) the CD3⁻TCRζ⁺ NK and the nonlymphocyte CD3⁻TCRζ⁻ cell subsets; *P = .066; **P < .047.